Prevention of Pneumocystic Pneumonia in Patients with Rheumatic Diseases: Problems and Solutions

Abstract

Currently, Immunosuppressive therapy Is becoming Increasingly common In the curation of patients with systemic rheumatic diseases (RH). However, the active use of immunosuppressors, including genetically engineered biological drugs is accompanied by an increase in opportunistic infections. The latter include pneumocystic pneumonia (PPn), which is a serious complication with significant mortality in patients with RA. Taking into account the heterogeneous risk data for specific RS and a particular immunosuppressive therapy, the establishment of evidence-based comprehensive guidelines for the prevention of PPn in rheumatology is not currently possible. Some guidelines for practicing physicians, published different collectives, can serve algorithms for the prevention of PPn, which will no doubt be further refined (or processed) the accumulation of new data.

Keywords

• pneumocystic pneumonia
• rheumatic diseases
• glucocorticoids
• cytostatics
• co-trimoxazole
• prevention